BRD9-Degrading Compounds for BAF-Related Cancer and Infection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for BAF complex-related disorders, such as cancer and infections, are inadequate due to the lack of effective agents that can reduce the levels and activity of BRD9, a component of the BAF complex, which is upregulated in multiple cancer cell lines and involved in cellular antiviral activities.
Innovation Solution
Development of compounds that degrade BRD9, including those with the structure of compound D1 or its pharmaceutically acceptable salts, which can be administered to inhibit BRD9 levels and activity in cells, thereby treating BAF-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for BAF complex-related disorders, then current treatment standards are maintained, but therapeutic effectiveness is insufficient and disease progression continues
Solution Approach 1:
The patent changes the molecular parameter by targeting BRD9 protein levels and activity through specific chemical compounds (e.g., compound D1 and its derivatives). These compounds modulate BRD9 expression and function, thereby altering the BAF complex's chromatin remodeling activity to achieve therapeutic effects in cancers and infections where BAF complex is dysregulated
Solution Approach 2:
The patent extracts and specifically targets the BRD9 component within the BAF complex for degradation or inhibition. By focusing on BRD9 as a critical subunit that can be selectively reduced (e.g., through proteasome-targeting compounds), the therapy achieves disruption of BAF complex function without requiring complete elimination of the entire complex, thereby improving therapeutic specificity and effectiveness
2Reliability
If agents that reduce BRD9 levels are developed, then therapeutic efficacy for cancer and infection is improved, but development complexity and research requirements increase
Solution Approach 1:
The patent identifies BRD9 as a universal target that serves multiple functions: it is a component of the BAF complex involved in chromatin remodeling for cancer progression, and simultaneously part of the antiviral response mechanism. Compounds targeting BRD9 (e.g., compound D1, D1-A, D1-B, D1-C, D1-D and their salts) can therefore address multiple disease states (cancer and viral infections) through a single therapeutic mechanism, reducing the need for separate drug development programs
Solution Approach 2:
The patent uses BRD9 as an intermediary target within the larger BAF complex. Instead of directly targeting the entire complex or multiple separate proteins, the therapy intermediates through BRD9 inhibition/degradation to achieve downstream effects on chromatin remodeling and viral response. This intermediary approach simplifies the therapeutic mechanism while maintaining broad efficacy
3Reliability
If BRD9 is targeted for degradation, then specific disease-related protein levels are reduced, but potential off-target effects and safety concerns may arise
Solution Approach 1:
The patent applies local quality by selectively targeting BRD9 within the context of the BAF complex in specific disease states. The compounds (e.g., compound D1 and derivatives) are designed to interact specifically with BRD9 in cancer cells and infected cells, where it is dysregulated, while having minimal effect on BRD9 in normal tissues. This selective targeting is achieved through the specific molecular structure of the compounds and their preference for BRD9 in pathological contexts
Data Source
AI summary
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.